PIRS (Pieris Pharmaceuticals) EBIT : $-18.10 Mil (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pieris Pharmaceuticals EBIT?

Pieris Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-3.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-18.10 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pieris Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2024 was -336.28%. Pieris Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pieris Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 215.16%.

Pieris Pharmaceuticals EBIT Historical Data

The historical data trend for Pieris Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals EBIT Chart

Pieris Pharmaceuticals Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-27.16

-33.92

-48.15

-35.30

-12.23

Pieris Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															3.09	-5.48	-5.30	-4.18	-3.14

Competitive Comparison of Pieris Pharmaceuticals's EBIT

For the Biotechnology subindustry, Pieris Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pieris Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's EV-to-EBIT falls into.

Pieris Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.10 Mil.

Pieris Pharmaceuticals (NAS:PIRS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pieris Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-12.54 * ( 1 - 0% )	/	( (4.121	+	3.337)	/ 2 )
=	-12.54	/	3.729
=	-336.28 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	25.051	-	2.225	-	( 19.731	-	max(0, 6.346	-	25.051	+	19.731	))
=	4.121

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	20.522	-	0.917	-	( 19.363	-	max(0, 4.254	-	20.522	+	19.363	))
=	3.337

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Pieris Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-12.54	/	( ( (0 + max(-4.212, 0))	+	(0 + max(-3.601, 0)) )	/	2 )
=	-12.54	/	( ( 0	+	0 )	/	2 )
=	-12.54	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.485	+	0	+	0.649)	-	(2.225	+	0	+	4.121)
=	-4.212

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.373	+	0	+	0.28)	-	(0.917	+	0	+	3.337)
=	-3.601

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pieris Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-18.097	/	-8.411
	=	215.16 %

Pieris Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pieris Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (NAS:PIRS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Franklin Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.pieris.com

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.

Executives

Ann Barbier	director	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Maya R. Said	director	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Matthew L Sherman	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Christopher P Kiritsy	director
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Shane Olwill	officer: Chief Development Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Ahmed Mousa	officer: Chief Business Officer	255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109
Hitto Kaufmann	officer: Chief Scientific Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Thomas Bures	officer: Chief Financial Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Tim Demuth	officer: Chief Medical Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Aquilo Capital Management, Llc	10 percent owner	ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104